Improved radionuclide antibody coupling
Abstract
Abstract Metal radionuclide labeled proteinaceous substances which contain, in their native states, disulfide (cysteine) linkages, which find use in diagnosis and treatment of a variety of pathologic conditions. The radionuclide labeled proteinaceous substances of the present invention are formed by the treatment of the proteinaceous substance of interest with a disulfide reducing agent, followed by reaction of the reduced proteinaceous substance ("H-treated product") with a suitable radionuclide species containing, for example, 99m Tc, ¹⁸⁶Re and ¹⁸⁸Re, or ⁶⁷Cu. It has been found that the H-treated products, e.g. , antibodies, react specifically with radionuclide species to form stable radionuclide labeled antibodies or other radiolabeled products. The H-treated products may be stabilized or modified in a variety of ways prior to and subsequent to complexation with the metal radionuclide.
Inventors
- 👤 John M. Reno
- 👤 Becky J. Bottino
Bibliographic Details
Claims Analysis
Total Claims: 10References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.